Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Keeter

Physician Assistant Fort Mill, SC Physician Assistant

NPI 1396997110 CMS profile 10839254

1700 1St Baxter Xing Ste 101, Fort Mill, SC 29708

Open in the dashboard

General payments

$129,367

865 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Keeter of Fort Mill, SC is reported in the CMS Open Payments database as having received $129,367 across 865 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,535 186
2024 General $47,042 235
2023 General $45,103 233
2022 General $9,920 121
2021 General $1,766 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Keeter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nicole Keeter were reported at $25,535. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nicole Keeter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,766 $132 $37–$438 $132
2022 $9,920 $155 $48–$522 $149
2023 $45,103 $167 $52–$557 $160
2024 $47,042 $178 $55–$600 $164
2025 $25,535 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $105,061 169 payments
  2. Janssen Scientific Affairs, LLC $7,107 19 payments
  3. UCB, Inc. $2,300 35 payments
  4. E.R. Squibb & Sons, L.L.C. $2,207 70 payments
  5. Novartis Pharmaceuticals Corporation $2,176 33 payments
  6. AbbVie, Inc. $2,109 139 payments
  7. Genzyme Corporation $1,128 39 payments
  8. Sun Pharmaceutical Industries Inc. $1,063 46 payments
  9. Lilly USA, LLC $893 32 payments
  10. Arcutis Biotherapeutics, Inc. $774 31 payments
  11. Other $4,548 252 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,012 46 payments
  2. Food and Beverage $19,169 751 payments
  3. Travel and Lodging $17,510 53 payments
  4. Consulting Fee $3,032 4 payments
  5. Education $643 11 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $112,116 186 payments
  2. Bimzelx $2,096 27 payments
  3. DUPIXENT $1,421 54 payments
  4. SOTYKTU $1,234 66 payments
  5. SKYRIZI $1,106 94 payments
  6. COSENTYX $1,073 10 payments
  7. VTAMA $982 69 payments
  8. TALTZ $848 30 payments
  9. RINVOQ $808 30 payments
  10. ILUMYA $733 37 payments
  11. Other $7,162 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

670

Median for Physician Assistant: 241

Drug cost

$487,731

Median for Physician Assistant: $4,110

Branded share of claims

9.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 28 $174,726
Taltz Autoinjector Ixekizumab Brand 25 $158,974
Tremfya Guselkumab Brand 11 $139,211
Doxycycline Hyclate Generic 93 $3,477
Clobetasol Propionate Generic 61 $2,509
Fluorouracil Generic 44 $2,431
Metronidazole Generic 44 $1,828
Fluocinonide Generic 37 $1,544
Triamcinolone Acetonide Generic 100 $1,132
Ketoconazole Generic 111 $1,096

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$88,600

Medicare's payments for the services billed

Medicare patients

605

Average age 75

Services billed

2,318

366 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 42%
Ischemic heart disease 23%
Cancer 18%
Osteoporosis 18%
Diabetes 17%
Depression 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$42,546 11 —
Bimzelx
$1,366 — —
DUPIXENT
$536 — —
SOTYKTU
$388 — —
VTAMA
$362 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

865 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record